跳转到内容

Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer

KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation — The post Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer appeared first on Bio Tech Winners.

Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
作者头像
LabNews Media LLC
labnews.ai 的主编是 Marita Vollborn 和 Vlad Georgescu。自 1994 年以来,他们一直是畅销书作家、科学作家和科学记者。更多关于他们的写作信息,请访问 X-Press Journalistenbüro (https://xpress-journalisten.com)。更多维基百科信息:关于 Marita:https://de.wikipedia.org/wiki/Marita_Vollborn 关于 Vlad:https://de.wikipedia.org/wiki/Vlad_Georgescu
LabNews Media LLC

LabNews Media LLC

labnews.ai 的主编是 Marita Vollborn 和 Vlad Georgescu。自 1994 年以来,他们一直是畅销书作家、科学作家和科学记者。更多关于他们的写作信息,请访问 X-Press Journalistenbüro (https://xpress-journalisten.com)。更多维基百科信息:关于 Marita:https://de.wikipedia.org/wiki/Marita_Vollborn 关于 Vlad:https://de.wikipedia.org/wiki/Vlad_Georgescu